| JaLCDOI | 10.18926/AMO/31598 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Kiura, Katsuyuki| Ohnoshi, Taisuke| Tabata, Masahiro| Shibayama, Takuo| Kimura, Ikuro| |
| Abstract | A subline highly resistant to Adriamycin (SBC-3/ADM100) was isolated in vitro from the human small cell lung cancer cell line, SBC-3, by culturing in progressively higher concentrations of Adriamycin. The SBC-3/ADM100 cells were 106-fold more resistant to the drug than the parent cells in an inhibitory concentration of 50% determined by the MTT assay. The population-doubling time was much longer in SBC-3/ADM100 than in the parent cells. Northern blot hybridization revealed marked overexpression of the MDR1 mRNA in the resistant cells. P-glycoprotein overexpression and a decrease in intracellular accumulation of Adriamycin were demonstrated in SBC-3/ADM100, indicating that outward drug transport was the major mechanism of resistance in this subline. Additionally, a significant elevation of the intracellular glutathione content coupled with the glutathione S-transferase (GST) pi level and a decrease in DNA topoisomerase II (Topo II) activity were noted in this resistant subline. These results indicate that the mechanism of resistance to Adriamycin is multifactorial; involving altered growth characteristics, an enhanced outward transport, enhanced drug detoxification process, and decreased target enzyme activity. The resistant subline will serve as a useful tool in the search for ways to overcome drug resistance. |
| Keywords | Adriamycin-resistant cell line MDR1 mRNA glutathione glutathione S-transferasse π DNA topoisomerase II |
| Amo Type | Article |
| Published Date | 1993-06 |
| Publication Title | Acta Medica Okayama |
| Volume | volume47 |
| Issue | issue3 |
| Publisher | Okayama University Medical School |
| Start Page | 191 |
| End Page | 197 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | Copyright © 1999 Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 8104372 |
| Web of Science KeyUT | A1993LL12400008 |
| Related Url | http://ousar.lib.okayama-u.ac.jp/metadata/6296 |
| JaLCDOI | 10.18926/AMO/31626 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Matsushita, Akio| Tabata, Masahiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Shibayama, Takuo| Aoe, Keisuke| Kohara, Hiroyuki| Harada, Mine| |
| Abstract | <p>We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a) Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b) Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c) Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.</p> |
| Keywords | drug screening system MTT assay lung cancer cell line drug resistance |
| Amo Type | Article |
| Published Date | 1999-04 |
| Publication Title | Acta Medica Okayama |
| Volume | volume53 |
| Issue | issue2 |
| Publisher | Okayama University Medical School |
| Start Page | 67 |
| End Page | 75 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| Web of Science KeyUT | 000080058700002 |
| JaLCDOI | 10.18926/AMO/31705 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Takata, Ichiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Katayama, Hideki| Takemoto, Mitsuhiro| Hiraki, Yoshio| Harada, Mine| Tanimoto, Mitsune| |
| Abstract | <p>A pilot study was conducted to assess the efficacy and feasibility of daily low-dose cisplatin with concurrent thoracic irradiation for clinically unresectable non-small-cell lung cancer (NSCLC). Patients with inoperable NSCLC who had poor risk factors such as advanced age, poor performance status, poor lung function, or concomitant active malignancy were entered into the study. Low-dose cisplatin (6 mg/m2) was administered daily before concurrent thoracic irradiation (2 Gy/day; total dose of 60 Gy) was given. Twenty-five patients were registered. The majority of the patients had either stage IIIA (24.0%) or stage IIIB (60.0%) disease. Fifteen patients (60.0%) completed the planned treatment. Both chemotherapy and radiotherapy were stopped in 3 patients (12.0%) due to poor response, and 7 patients (28.0%) partly received radiotherapy alone as a result of their toxicity response. The proportion of total administered dose to planned dose was 90.9% for chemotherapy and 99.3% for radiotherapy, which were comparable to those in previous studies for LA-NSCLC patients without poor risk factors. Grade 3 leukopenia and neutropenia developed in 14 patients (56.0%) and 10 patients (40.0%), respectively, but grade 4 toxicity was not encountered. Grade 3 pneumonitis and esophagitis were observed in 4 patients (16.0%) and 2 patients (8.0%), respectively. The overall response rate was 60.0%. The median survival time was 22 months, and the 2-year survival rate was 50.3%. Daily low-dose cisplatin and concurrent thoracic irradiation were well tolerated even by poor-risk patients with NSCLC, and showed a therapeutic efficacy similar to that for good-risk patients.</p> |
| Keywords | non-small-cell lung cancer concurrent chemoradiotherapy low-dose cisplatin poor-risk factor |
| Amo Type | Article |
| Published Date | 2002-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume56 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 261 |
| End Page | 266 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 12530510 |
| Web of Science KeyUT | 000178668100007 |
| JaLCDOI | 10.18926/AMO/31714 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Kawada, Kazuhiko| Yonei, Toshiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Harada, Mine| Tanimoto, Mitsune| |
| Abstract | <p>When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.</p> |
| Keywords | chemosensitivity test 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltertrazolium bromide (MTT) assay clonogenic assay |
| Amo Type | Article |
| Published Date | 2002-06 |
| Publication Title | Acta Medica Okayama |
| Volume | volume56 |
| Issue | issue3 |
| Publisher | Okayama University Medical School |
| Start Page | 129 |
| End Page | 134 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 12108583 |
| Web of Science KeyUT | 000176521200002 |
| JaLCDOI | 10.18926/AMO/32866 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Fujimoto, Nobukazu| Kiura, Katsuyuki| Takigawa, Nagio| Fujiwara, Yoshiro| Toyooka, Shinichi| Umemura, Shigeki| Tabata, Masahiro| Ueoka, Hiroshi| Tanimoto, Mitsune| |
| Abstract | <p>We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were <70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.</p> |
| Keywords | cisplatin docetaxel irinotecan triplet chemotherapy gefitinib |
| Amo Type | Original Article |
| Published Date | 2010-02 |
| Publication Title | Acta Medica Okayama |
| Volume | volume64 |
| Issue | issue1 |
| Publisher | Okayama University Medical School |
| Start Page | 33 |
| End Page | 37 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 20200582 |
| Web of Science KeyUT | 000274868300005 |
| Title Alternative | A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy |
|---|---|
| FullText URL | 127_127.pdf |
| Author | Kiura, Katsuyuki| Hotta, Katsuyuki| Sato, Akiko| Ohashi, Kadoaki| Ninomiya, Takashi| Minnami, Daisuke| Tabata, Masahiro| Kubo, Toshio| Kato, Yuka| Hirata, Taizo| |
| Keywords | 臨床研究中核病院 国立研究開発法人日本医療研究開発機構 文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2015-08-03 |
| Volume | volume127 |
| Issue | issue2 |
| Start Page | 127 |
| End Page | 132 |
| ISSN | 0030-1558 |
| Related Url | isVersionOf https://doi.org/10.4044/joma.127.127 |
| language | 日本語 |
| Copyright Holders | Copyright (c) 2015 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.127.127 |
| NAID | 130005096256 |
| JaLCDOI | 10.18926/AMO/54499 |
|---|---|
| FullText URL | 70_4_243.pdf |
| Author | Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki| |
| Abstract | Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p＜0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation. |
| Keywords | vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse |
| Amo Type | Original Article |
| Published Date | 2016-08 |
| Publication Title | Acta Medica Okayama |
| Volume | volume70 |
| Issue | issue4 |
| Publisher | Okayama University Medical School |
| Start Page | 243 |
| End Page | 253 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27549668 |
| Web of Science KeyUT | 000384748600003 |
| FullText URL | J_Thorac_Oncol_201907017.pdf |
|---|---|
| Author | Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | ALK G1202R Alectinib Amphiregulin MET NSCLC |
| Published Date | 2019-07-30 |
| Publication Title | Journal of Thoracic Oncology |
| Volume | volume14 |
| Issue | issue11 |
| Publisher | Elsevier |
| Start Page | 2009 |
| End Page | 2018 |
| ISSN | 15560864 |
| NCID | AA12058455 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. |
| File Version | author |
| PubMed ID | 31374369 |
| DOI | 10.1016/j.jtho.2019.07.017 |
| Web of Science KeyUT | 000492678300025 |
| Related Url | isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Nishii, Kazuya| Ohashi, Kadoaki| Tamura, Tomoki| Ninomiya, Kiichiro| Matsubara, Takehiro| Senoo, Satoru| Kano, Hirohisa| Watanabe, Hiromi| Oda, Naohiro| Makimoto, Go| Higo, Hisao| Kato, Yuka| Ninomiya, Takashi| Kubo, Toshio| Yamamoto, Hiromasa | Tomida, Shuta| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | non-small cell lung cancer epidermal growth factor receptor mutations droplet digital PCR exhaled breath condensate EGFR-TKIs |
| Published Date | 2020-12 |
| Publication Title | Oncology Letters |
| Volume | volume20 |
| Issue | issue6 |
| Publisher | Spandidos Publications |
| Start Page | 393 |
| ISSN | 1792-1074 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| File Version | publisher |
| PubMed ID | 33193853 |
| DOI | 10.3892/ol.2020.12256 |
| Web of Science KeyUT | 000595649300005 |
| Related Url | isVersionOf https://doi.org/10.3892/ol.2020.12256 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Watanabe, Hiromi| Ichihara, Eiki| Kayatani, Hiroe| Makimoto, Go| Ninomiya, Kiichiro| Nishii, Kazuya| Higo, Hisao| Ando, Chihiro| Okawa, Sachi| Nakasuka, Takamasa| Kano, Hirohisa| Hara, Naofumi| Hirabae, Atsuko| Kato, Yuka| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ohashi, Kadoaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Published Date | 2021-01-07 |
| Publication Title | Cancer science |
| Publisher | Wiley |
| ISSN | 1347-9032 |
| NCID | AA11808050 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2021 The Authors. |
| File Version | publisher |
| PubMed ID | 33410241 |
| NAID | 120007008532 |
| DOI | 10.1111/cas.14801 |
| Web of Science KeyUT | 000630136900001 |
| Related Url | isVersionOf https://doi.org/10.1111/cas.14801 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Katsui, Kuniaki| Ogata, Takeshi| Sugiyama, Soichi| Yoshio, Kotaro| Kuroda, Masahiro| Hiraki, Takao| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu| |
| Published Date | 2021-06-04 |
| Publication Title | scientific reports |
| Volume | volume11 |
| Issue | issue1 |
| Publisher | Nature Research |
| Start Page | 11882 |
| ISSN | 2045-2322 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © The Author(s) 2021 |
| File Version | publisher |
| PubMed ID | 34088965 |
| DOI | 10.1038/s41598-021-91449-z |
| Web of Science KeyUT | 000678611200010 |
| Related Url | isVersionOf https://doi.org/10.1038/s41598-021-91449-z |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Okawa, Sachi| Rai, Kammei| Fujii, Nobuharu| Gion, Yuka| Ninomiya, Kiichiro| Kato, Yuka| Taniguchi, Akihiko| Kubo, Toshio| Ichihara, Eiki| Ohashi, Kadoaki| Miyahara, Nobuaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | EGFR IgG4-related disease marginal zone lymphoma osimertinib |
| Published Date | 2021-09-01 |
| Publication Title | Internal Medicine |
| Volume | volume60 |
| Issue | issue17 |
| Publisher | The Japanese Society of Internal Medicine |
| Start Page | 2831 |
| End Page | 2837 |
| ISSN | 0918-2918 |
| NCID | AA10827774 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2021 The Japanese Society of Internal Medicine |
| File Version | publisher |
| PubMed ID | 33775999 |
| DOI | 10.2169/internalmedicine.6470-20 |
| Web of Science KeyUT | 000695856000020 |
| Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.6470-20 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Oda, Naohiro| Tabata, Masahiro| Uno, Masatoshi| Umeda, Yuzo| Kato, Hironari| Kubo, Toshio| Senoo, Satoru| Yagi, Takahito| Fujiwara, Toshiyoshi| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | pancreas mucinous cystadenocarcinoma carboplatin paclitaxel |
| Published Date | 2021-09-15 |
| Publication Title | Internal Medicine |
| Volume | volume60 |
| Issue | issue18 |
| Publisher | The Japanese Society of Internal Medicine |
| Start Page | 2967 |
| End Page | 2971 |
| ISSN | 0918-2918 |
| NCID | AA10827774 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2021 The Japanese Society of Internal Medicine |
| File Version | publisher |
| PubMed ID | 33814494 |
| DOI | 10.2169/internalmedicine.6730-20 |
| Web of Science KeyUT | 000697279400013 |
| Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.6730-20 |
| FullText URL | fulltext20210810-3.pdf |
|---|---|
| Author | Nishii, Kazuya| Ohashi, Kadoaki| Watanabe, Hiromi| Makimoto, Go| Nakasuka, Takamasa| Higo, Hisao| Ninomiya, Kiichiro| Kato, Yuka| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | epidermal growth factor receptor osimertinib bevacizumab cetuximab hypoxia‑inducible factor‑1α transforming growth factor‑α |
| Published Date | 2021-7-7 |
| Publication Title | Oncology Letters |
| Volume | volume22 |
| Issue | issue3 |
| Publisher | Spandidos Publications |
| Start Page | 639 |
| ISSN | 1792-1074 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © Nishii et al. This is an open access article distributed under the terms of Creative Commons Attribution License. |
| File Version | publisher |
| DOI | 10.3892/ol.2021.12900 |
| Web of Science KeyUT | 000678494600001 |
| Related Url | isVersionOf https://doi.org/10.3892/ol.2021.12900 |
